Jolt Health To Acquire HCQ Transdermal Patch Technology

FDA Approved and Viability to Address Underserved Lupus, Rheumatoid Arthritis and Malaria market, forecast to be worth $6 Billion USD by 2027*

VANCOUVER, BC / ACCESSWIRE / May 6, 2024 / Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT)(FSE:G1Q0) is pleased to announce an arms-length agreement dated April 16, 2024 to acquire intellectual property to develop transdermal delivery technology for chloroquine and hydroxychloroquine that will add to its health and wellness portfolio with significant biotechnology assets.

Jolt will acquire several provisional patents and patent applications in the US, Europe and other countries for transdermal and oral mucosal delivery of hydroxychloroquine (HCQ) and chloroquine (CQ), along with all related intellectual property covering a large geography of potential patient populations. HCQ is already FDA approved as a treatment against malaria, lupus, and rheumatoid arthritis when delivered orally.

While HCQ gained some notoriety as a possible cure for Covid during the recent pandemic, the Company is focused on the application of HCQ in a transdermal patch for the underserved patients with malaria, lupus, and rheumatoid arthritis. Current oral tablet delivery of HCQ comes with side effects that transdermal delivery is likely to resolve.

Highlights

• Market for HCQ forecast to reach $6 billion by 2027* as FDA approved treatment for malaria, lupus, and rheumatoid arthritis.
• Jolt is acquiring positive technical feasibility study results indicating HCQ has all the required parameters to be delivered transdermally.
• HCQ transdermal treatment for malaria, lupus and rheumatoid arthritis patients likely to resolve oral tablet side effects as it would bypass the first pass metabolism.
• This transformative delivery system will initially seek approval through the FDA 505(b)(2) accelerated pathway provisions.

Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time. Safe, consistent doses will make the drug much more effective at reduced dosages required because the GI system is avoided with transdermal delivery. This new delivery method should eliminate or reduce a number of the common side effects of the oral tablet treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache, by providing controlled constant delivery.